Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02217345

Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease — NAFLD  

Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trial

Official title:
Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease

Clinical Trial Summary

Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. NAFLD is expected to be the most common indication for liver transplantation by the year 2020. We hypothesize that growth hormone (GH) replacement will decrease intrahepatic lipid accumulation as quantified by 1H magnetic resonance spectroscopy (1H-MRS).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02217345
Study type Interventional
Source Massachusetts General Hospital
Contact
Status Completed
Phase Phase 2
Start date June 2, 2017
Completion date September 13, 2021
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02244944 - Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD Phase 2
Recruiting NCT01544751 - Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin N/A
Recruiting NCT03572465 - Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
Enrolling by invitation NCT04059029 - Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients
Terminated NCT01930123 - Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease Phase 2
Recruiting NCT01705522 - Multimodal Approach in IBD Patients
Recruiting NCT03525769 - Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes
Recruiting NCT06024408 - A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor Phase 1
Completed NCT01265498 - The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) Phase 2
Completed NCT01529268 - Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children Phase 2/Phase 3
Completed NCT03486899 - A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis Phase 2
Completed NCT02781584 - Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) Phase 2
Completed NCT03486912 - A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Phase 2
Completed NCT02196831 - Tesamorelin Effects on Liver Fat and Histology in HIV N/A
Withdrawn NCT03451279 - A Nonabsorbable Ileal Apical Sodium-Dependent Bile Acid Transporter Inhibitor for Nonalcoholic Steatohepatitis Phase 2
Completed NCT02044523 - Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound
Completed NCT03836443 - Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease N/A
Completed NCT03042767 - Anti-LPS Antibody Treatment for Pediatric NAFLD Phase 2
Recruiting NCT02213224 - Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Phase 4
Completed NCT03459079 - Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease Phase 2